Fig. 4
From: Efficiently targeted therapy of glioblastoma xenograft via multifunctional biomimetic nanodrugs
Examinations of the uptake of CMS/PEG-DOX-M or CMS/PEG-DOX into U87 MG and HA cells by confocal microscopy and flow cytometry. A, B Confocal images of U87 MG cells treated with CMS/PEG-DOX-M (A) or CMS/PEG-DOX (B) at the indicated time points (scale bar 20 μm). Blue and red colors represent DAPI and DOX fluorescence, respectively. C, D Flow cytometry images showing the DOX uptake into U87 MG cells (C) and HA cells (D) treated with either of the indicated treatments at the indicated time points. E-F MFI of DOX in U87 MG cells (E) or HA cells (F) treated with CMS/PEG-DOX-M or CMS/PEG-DOX detected by flow cytometry at the indicated time points. CMS, Cu2MoS4; PEG, polyethylene glycol; DOX, doxorubicin; M, cell membrane of U87 MG cells, DAPI, 4′,6-diamidino-2-phenylindole